These include nausea, vomiting, diarrhoea, constipation, abdominal pain, and reduced appetite
Cost is your primary concern
Food and Drug Administration (FDA) approval for that use
This review provides (1) insights into the pathogenesis of NAFLD including the potential involvement of GLP-1 and glucagon, (2) a critical appraisal of the applicability of GLP-1RAs in NAFLD treatment, and (3) a review of the evidence for GLP-1/glucagon receptor co-agonism as a novel approach in the treatment of NAFLD
Results After removing incomplete and inconsistent responses, 16,461 responses (63% females) from 29 countries were analyzed
Warnings and precautions It is important to remember that retatrutide is not yet approved by the FDA for weight loss or any other indication